News and Events
February 27, 2025
MyOme Announces Launch of CAD iPRS and Beginning Enrollment in the COMPASS-CAD Prospective Trial
MyOme, Inc., a leading clinical whole genome testing and polygenic risk modelling (PRS) company, is proud to announce the launch of its coronary artery disease (CAD) PRS product – Integrated PRS, CAD (CAD iPRS)
January 30, 2025
MyOme and Novi Health Collaborate to Bring Whole Genome Testing to Employer Health Programs
MyOme has partnered with Novi Health to bring whole genome sequencing, polygenic risk modeling, and personalized genetic counseling to employees as part of workplace health benefits, empowering participants to take preventative action against common and hereditary conditions.
December 9, 2024
Natera and MyOme Announce Launch of iPRS™ for Breast Cancer Risk Assessment
Cross-ancestry polygenic risk score now offered with the Empower™ hereditary cancer test …
October 14, 2024
MyOme and Broad Clinical Labs to Support Southern Research Program to Bring Genetics-Driven Health Insights to Alabamians Free of Charge
Initiative to Empower the Underserved Community of Patients and Providers with Access to Personal Health Risks and Actionable Information to Prevent or Treat Disease…
November 2, 2023
MyOme Presents New Data: Improved 10-year Risk Prediction of Coronary Artery Disease through Polygenic Risk Scores Integrated with Clinical Factors Showcased at the American Society of Human Genetics Annual Meeting
Integrated polygenic risk score more accurately identified individuals at elevated risk for developing coronary artery disease, especially within borderline or intermediate clinical risk categories and for South Asian individuals…
March 16, 2023
MyOme Presents New Data on an Integrated Polygenic Risk Score to Improve Coronary Artery Disease Prediction at the American College of Medical Genetics and Genomics Annual Meeting
Integrated polygenic risk score can more accurately identify people at high risk of developing coronary artery disease across diverse ancestries over a commonly used clinical…
February 22, 2023
MyOme, Natera Show Cross-Ancestry Polygenic Risk Score Improves Breast Cancer Prediction -GenomeWeb
From GenomeWeb: 'NEW YORK – Personalized genomics company MyOme's cross-ancestry, integrated risk score (caIRS) improved breast cancer prediction over the standard Tyrer-Cuzick (T-C) model…'
February 22, 2023
MyOme Announces Publication of a Validated Cross-Ancestry Polygenic Risk Score for Breast Cancer
Data demonstrates improved breast cancer risk prediction across multiple ancestries over standard of care…
October 27, 2022
MyOme Presents New Data at ASHG 2022 on an Ethnically-Inclusive Breast Cancer Risk Assessment
Addition of a cross-ancestry polygenic risk score to the standard of care clinical risk predictor tool improved breast cancer risk assessment across multiple ancestries…
June 21, 2022
MyOme Secures $23M in Series B Funding to Deliver Clinical Whole Genome Insights to Help Families Manage Risk for Inherited Diseases
The oversubscribed series B financing led by Healthcare Venture Partners, added SoftBank Corp. and Natera to existing investors– Sequoia Capital, Foresite Capital, Founders Fund, …
June 16, 2022
Equity Issues, Admixed Populations Continue to Complicate Use of Polygenic Risk Scores — GenomeWeb
A dearth of genome-wide association studies focused on non-European populations, plus issues related to applying polygenic risk scores in populations with multiple ancestries, has spurred…
June 15, 2022
MyOme Develops Cross-Ancestry Breast Cancer Polygenic Risk Score, Plans Product Launch — GenomeWeb
NEW YORK – Personalized genomics company MyOme presented data at the recent American Society of Clinical Oncology conference demonstrating its ability to train and validate…
June 1, 2022
MyOme Presents New Data at ASCO 2022 on Cross-ancestry Polygenic Risk Score for Breast Cancer
MyOme Presents New Data at ASCO 2022 on Cross-ancestry Polygenic Risk Score for Breast CancerStudy highlights potential of Polygenic Risk Scores (PRS) to improve breast…
April 6, 2022
Is it time to test embryos for common diseases? — MedicalXpress.com
A Silicon Valley company has designed a technique to decipher the genetic code of a tiny embryo and calculate its future risk of cancer, diabetes…